BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31278574)

  • 1. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
    Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.
    Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
    J Nucl Med; 2017 Feb; 58(2):266-275. PubMed ID: 27635027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
    Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
    Br J Surg; 2017 Mar; 104(4):408-417. PubMed ID: 28093719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
    Findlay JM; Gillies RS; Franklin JM; Teoh EJ; Jones GE; di Carlo S; Gleeson FV; Maynard ND; Bradley KM; Middleton MR
    Eur Radiol; 2016 Oct; 26(10):3519-33. PubMed ID: 26883329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routinely staging gastric cancer with
    Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
    Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
    Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy.
    Jimenez-Jimenez E; Mateos P; Ortiz I; Aymar N; Roncero R; Gimenez M; Pardo J; Sabater S
    Clin Transl Oncol; 2019 Sep; 21(9):1159-1167. PubMed ID: 30661172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
    Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
    Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
    Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
    BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
    Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
    J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    van der Aa DC; Gisbertz SS; Anderegg MCJ; Lagarde SM; Klaassen R; Meijer SL; van Dieren S; Hulshof M; Bergman J; Bennink RJ; van Laarhoven HWM; van Berge Henegouwen MI
    J Gastrointest Cancer; 2024 Mar; 55(1):270-280. PubMed ID: 37393217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
    Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
    Gillies RS; Middleton MR; Han C; Marshall RE; Maynard ND; Bradley KM; Gleeson FV
    Br J Surg; 2012 Feb; 99(2):239-45. PubMed ID: 22329010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of dynamic contrast-enhanced MRI and
    Withey SJ; Owczarczyk K; Grzeda MT; Yip C; Deere H; Green M; Maisey N; Davies AR; Cook GJ; Goh V;
    Eur J Surg Oncol; 2023 Oct; 49(10):106934. PubMed ID: 37183047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer.
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Br J Surg; 2013 Oct; 100(11):1490-7. PubMed ID: 24037571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.